Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Abbisko builds combination strategy with China rights to X4's mavorixafor

July 17, 2019 12:02 AM UTC

Abbisko has licensed Greater China rights to X4’s mavorixafor, which the Shanghai-based company plans to use to develop a pipeline of combination therapies.

The deal, for which financial terms are not disclosed, gives Abbisko Therapeutics Co. Ltd. exclusive rights to develop and commercialize the CXCR4 antagonist in China, Taiwan, Hong Kong and Macao for oncology indications...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article